Citation data

OpenAlex

Works that cite this article, indexed by OpenAlex.

71 resultsUpdated November 08, 2026

← Back to article

Diabetic Kidney Disease

Medical Clinics of North America 107(4) (2023)

Sonali Gupta; Mary Dominguez; Ladan Golestaneh

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors

International Journal of Molecular Sciences 23(7) (2022)

Teresa Salvatore; Raffaele Galiero; Alfredo Caturano; Luca Rinaldi; Anna Di Martino; Gaetana Albanese; Jessica Di Salvo; Raffaella Epifani; Raffaele Marfella; Giovanni Docimo; Miriam Lettieri; Celestino Sardu; Ferdinando Carlo Sasso

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics

Theranostics 11(9) (2021)

Zhenghong Liu; Xiaoxuan Ma; Iqra Ilyas; Xueying Zheng; Sihui Luo; Peter J. Little; Danielle Kamato; Amirhossein Sahebkar; Weiming Wu; Jianping Weng; Suowen Xu

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study

Diabetologia 66(10) (2023)

Matthew Anson; Sizheng Steven Zhao; Philip J. Austin; Gema Hernández; Rayaz Ahmed Malik; Uazman Alam

Renoprotective mechanisms of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease

Journal of Cellular Physiology 237(2) (2021)

Sreenithya Ravindran; Shankar Munusamy

Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study

The Journal of Clinical Endocrinology & Metabolism 108(4) (2022)

Khary Edwards; Xilong Li; Ildiko Lingvay

Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials

Diabetes Therapy 11(2) (2019)

David M. Williams; Asif Nawaz; Marc Evans

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

Clinical and Molecular Hepatology 27(2) (2020)

Karn Wijarnpreecha; Elizabeth S. Aby; Aijaz Ahmed; Donghee Kim

Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes

BMC Nephrology 21(1) (2020)

Gregory A. Nichols; Anouk Déruaz‐Luyet; Kimberly Goodnow Brodovicz; Teresa M. Kimes; A. Gabriela Rosales; Sibylle Jenny Hauske

Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes

Kidney International Reports 6(8) (2021)

Hongyan Liu; Vikas S. Sridhar; Leif Erik Lovblom; Yuliya Lytvyn; Dylan E Burger; Kevin D. Burns; Davor Brinc; Patrick R. Lawler; David Z.I. Cherney

Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea

Pharmacology Research & Perspectives 10(1) (2022)

Hyeri Yang; Eunmi Choi; Eunjun Park; Eonji Na; Soo Youn Chung; Bong Gi Kim; Soon Young Han

Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK

Diabetes Therapy 11(9) (2020)

Mafalda Ramos; Michael H. Cummings; Anastasia Ustyugova; Syed I. Raza; Shamika U. de Silva; Mark Lamotte

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors

Diabetes Metabolic Syndrome and Obesity Volume 11 (2018)

Tricia Santos Cavaiola; Jeremy Pettus

Associations between second‐line glucose‐lowering combination therapies with metformin and HbA1c , body weight, quality of life, hypoglycaemic events and glucose‐lowering treatment intensification: The DISCOVER study

Diabetes Obesity and Metabolism 23(8) (2021)

Kamlesh Khunti; Bernard H. Charbonnel; Andrew Cooper; Marília Brito Gomes; Linong Ji; Paul Leigh; Antonio Nicolucci; Wolfgang Rathmann; Marina Vladimirovna Shestakova; Afrah Siddiqui; Fengming Tang; Hirotaka Watada; Hungta Chen; the DISCOVER investigators

Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care

Biomedicines 12(9) (2024)

Alfredo Caturano; Raffaele Galiero; Maria Paola Rocco; Giuseppina Tagliaferri; Alessia Piacevole; Davide Nilo; Giovanni Di Lorenzo; Celestino Sardu; Erica Vetrano; Marcellino Monda; Raffaele Marfella; Luca Rinaldi; Ferdinando Carlo Sasso

Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment

Therapeutic Advances in Endocrinology and Metabolism 14 (2023)

Khary Edwards; Aleksandra A. Uruska; Anna Duda‐Sobczak; Dorota Zozulińska‐Ziółkiewicz; Ildiko Lingvay

SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM

Scientific Reports 15(1) (2025)

Birdie Huang; Chieh‐Li Yen; Chao‐Yi Wu; Chung‐Ying Tsai; Jia‐Jin Chen; Ching-Chung Hsiao; Yung‐Chang Chen; I-Chang Hsieh; Huang‐Yu Yang

Ketone bodies in renal function and diabetic kidney disease

The Journal of Nutritional Biochemistry 142 (2025)

Hamza Mechchate

Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients

Journal of Diabetes Investigation 12(1) (2020)

Atsunori Kashiwagi; Shinchi Araki; Hiroshi Maegawa

DIABETES AND RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM: IMPLICATIONS FOR COVID-19 PATIENTS WITH DIABETES TREATMENT MANAGEMENT

FARMACIA 68(3) (2020)

Doina Catrinoiu

The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice

FEBS Open Bio 10(12) (2020)

Zi Li; Maki Murakoshi; Saki Ichikawa; Takeo Koshida; Eri Adachi; Chigure Suzuki; Seiji Ueda; Tomohito Gohda; Yusuke Suzuki

Type 2 Diabetes in Youth

Global Pediatric Health 7 (2020)

Goutham Rao; Elizabeth T. Jensen

Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double‐blind placebo‐controlled trial (EMPT‐ANGINA Trial)

Clinical Cardiology 47(1) (2023)

Mohammad Hadi Mansouri; Pejman Mansouri; Masoumeh Sadeghi; Seyedeh Melika Hashemi; Alireza Khosravi; Mohaddeseh Behjati; Javad Shahabi; Asieh Mansouri; Reihaneh Zavar; Afshin Amirpour; Hamid Sanei; Nizal Sarrafzadegan

Prevalence of Bacterial Urinary Tract Infection Among Patients With Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study

Journal of the ASEAN Federation of Endocrine Societies 37(2) (2022)

Pankaj Ferwani; Aasim N. Maldar; Nishitkumar F. Shah; Phulrenu Shah; Manoj D. Chadha

Carbohydrate metabolism in chronic renal disease

Elsevier eBooks (2021)

Marcin Adamczak; Eberhard Ritz; Andrzej Więcek

Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus

Indian Journal of Pharmacology 55(2) (2023)

Debdipta Bose; Miteshkumar Rajaram Maurya; Mahanjit Konwar

Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2

Journal of Clinical and Translational Hepatology 10(5) (2022)

Emmanouil Koullias; John S. Koskinas

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population

Diabetes Metabolic Syndrome and Obesity Volume 14 (2021)

Lianglan Shen; Hongli Yang; Xingxing Fang; Huaxing Huang; Wubin Yao; Dongmei Chen; Yan Shen

Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination

touchREVIEWS in Endocrinology 17(1) (2021)

JOHAN H. JENDLE; Francisco Javier Ampudia‐Blasco; Martin Füchtenbusch; Paolo Pozzilli

Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy

Acta Diabetologica 63(3) (2025)

Utku Erdem Soyaltın; İlgın Yıldırım Şimşir; Barış Akıncı

Diastolic dysfunction and impaired cardiac output reserve in dysmetabolic nonhuman primate with proteinuria

Journal of Diabetes and its Complications 35(4) (2021)

Johannes Wikström; Yongqiang Liu; Carl A. Whatling; Li‐Ming Gan; Peter Könings; Binchen Mao; Chao Zhang; Yanqin Ji; Yong‐Fu Xiao; Yixin Wang

A practical review of diabetes mellitus type 2 treatment in primary care

Romanian Journal of Internal Medicine 60(1) (2021)

Justin T. Call; Pedro Cortés; Dana M. Harris

Relationship between dapagliflozin and urinary albumin-to-creatinine ratio in patients with diabetes mellitus and cardiovascular disease: an observational study

Cardiology Plus 8(4) (2023)

Zejia Wu; Xuyu He; Shuang Xia; Xiaoju Xiao; Jiyan Chen; Liwen Li

Effect of Add-On Therapy of Dapagliflozin and Empagliflozin on Adipokines in Type 2 Diabetes Mellitus

Journal of Endocrinology and Metabolism 11(3-4) (2021)

Abid Shaheer; Ashok Kumar; Palat Balachandran Menon; Mahir Khalil Ibrahim Jallo; Shaikh Altaf Basha

Sodium-glucose Co-transporter-2 inhibitors (SGLT2I): A class of drugs with promising cardiorenal protective effects beyond glycemic control

Annals of Medicine and Surgery 81 (2022)

Abdullah Zaawari; Aaminah Najmus Sahar

Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients

Scientific Reports 13(1) (2023)

Sanghwa Park; Jiseon Jeong; Yunna Woo; Yeo Jin Choi; Sooyoung Shin

Effect of SGLT2 inhibitors on kidney function of type 2 diabetes patients during Ramadan: A systematic review

Qatar medical journal 2024(3) (2024)

Muhammad Aamir Waheed; Salah Suwileh; Khalid Rashid; Farrukh Ansar; Abdel-Naser Y Elzouki

Anti-diabetic Agents and the Potentials for Reducing Cardiovascular Risks in Type-2 Diabetes Mellitus

Annals of Health Research (The Journal of the Medical and Dental Consultants Association of Nigeria OOUTH Sagamu Nigeria) 7(3) (2021)

Ignatius Ugochukwu Ezeani; Aihanuwa Eregie; Augustine Efedaye Ohwovoriole

Factors Associated with Response to SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes Mellitus

Journal of Clinical Medicine 14(12) (2025)

Gunjan Arora; Sulman Hashmi; Kaeli K. Samson; Sarah Khozema Hussain Azad; Jaskaran Batra; Vijaya deepika Perugu; Clifton Davis; Cyrus V Desouza

SGLT2-inhibition and myocardial infarction size in patients with type 2 diabetes mellitus– Insights from an acute cardiovascular care center

BMC Cardiovascular Disorders 25(1) (2025)

István Bojti; Felicitas Bojti; Tau Sarra Hartikainen; Philipp Breibart; Nikolaus Löffelhardt; Christian Marc Valina; Kilian Franke; Klaus Kaier; Dennis Wolf; Dirk Westermann; Christoph B. Olivier

Cardioprotective effectiveness of SGLT2 inhibitors in older diabetic women with early-stage breast cancer following anthracycline- and/or trastuzumab-based treatment

Therapeutic Advances in Medical Oncology 17 (2025)

Yi‐Shao Liu; Jamie C. Barner; Kenneth A. Lawson; Yan Liu; Chanhyun Park

ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes

Advances in Therapy 42(12) (2025)

Rodrigo O. Moreira; Nemencio Almare Nicodemus; Abdurrahman Çömlekçi; Miao Yu; Mussa Almalki

Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy

World Journal of Cardiology 13(12) (2021)

Mouhamed Nashawi; Mahmoud S Ahmed; Toka Amin; Mujahed Abualfoul; ROBERT J. CHILTON

Метаболічні ефекти інгібіторів натрійзалежного котранспортера глюкози 2 типу

Clinical endocrinology and endocrine surgery(4) (2022)

А. В. Кедик; O. O. Kutsin

Cetoacidosis Diabética Euglucémica, un diagnostico difícil de identificar

Galicia Clínica 82(1) (2021)

M�rio Monteiro; Telma Elias; C�rmen Ferreira; Daniela Aquino de Brito

Cost-effectiveness analysis of Dapagliflozin versus Canagliflozin in treatment of type 2 diabetes mellitus

Journal of Applied Pharmaceutical Science 12(3) (2022)

Sadagoban Gopal Krishnamoorthy; Jemi Rachel Shaji; Premnath Bhagya; Siby Akshitha Rani; Swathi Swaroopa Borra; M Ayilya; Arun Kanniyappan Parthasarathy

Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes

Healthcare 10(7) (2022)

Irina Claudia Anton; Liliana Mititelu-Tarțău; T. Popa; Mihaela Poroch; Vladimir Poroch; Delia Reurean‐Pintilei; Gina Eosefina Botnariu

Metabolic effects of empagliflozine

Diabetes Obesity Metabolic Syndrome(5) (2022)

А. В. Кедик; O. O. Kutsin

SGLT-2 Inhibitors and Their Correlation With Kidney Stones. A Systematic Review

Journal of Health and Rehabilitation Research 4(2) (2024)

Bander J. Alshehri; Hani Shalabi

Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus

Frontiers in Endocrinology 16 (2025)

Haoyi Yang; Yuwen Zhang; Yuxin Hong; Yuan Wei; Yuning Zhu; Lei Huang; Yuanxun Yang; Runbin Sun; Juan Li

Correction to: Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes

BMC Nephrology 21(1) (2020)

Gregory A. Nichols; Anouk Déruaz‐Luyet; Kimberly Goodnow Brodovicz; Teresa M. Kimes; A. Gabriela Rosales; Sibylle Jenny Hauske

Diabetes mellitus: an important risk factor for peripheral vascular disease

Expert Review of Cardiovascular Therapy 18(3) (2020)

Stefanos Giannopoulos; Ehrin J. Armstrong

Do we have enough evidence to support the use of SGLT2 inhibitors for MACE reduction in patients with advance kidney disease?

European Journal of Internal Medicine 70 (2019)

Rajkumar Prakashbhai Doshi; Zahara Meghji; Ashish R. Kumar; Mariam Shariff; Devina Adalja

Risk factors and pharmacological therapy in patients with vascular disease

Elsevier eBooks (2021)

Giuseppe Maiolino; Marco Rossato; Roberto Vettor

Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination

touchREVIEWS in Endocrinology 1(1) (2021)

JOHAN H. JENDLE; Francisco Javier Ampudia‐Blasco; Martin Füchtenbusch; Paolo Pozzilli

Clinical practice guidelines update 2022: Focus on diabetes

Pharmacy Today 28(6) (2022)

Susan A. Cornell

The Evaluation of Cardiovascular Risk in Diabetic Patients

European Pharmaceutical Journal 69(1) (2022)

Stanislava Kosírová; Dominika Rubintova; J. Lacka; Ján Klimas; Tatiana Foltánová; I Tůmová

A Randomized, Double-blind, Active-controlled Study of Remogliflozin Etabonate 100 mg plus Teneligliptin 10 mg Twice-daily versus Teneligliptin 20 mg Oncedaily as add-on to Metformin Monotherapy in Indian Diabetic Patients

Journal of Diabetes and Treatment 7(2) (2022)

Rahul Kodgule

Investigação dos efeitos da empagliflozina sobre a heterogeneidade da repolarização ventricular em pacientes com diabetes e doença arterial coronariana

Digital Library of Theses and Dissertations (Universidade de São Paulo) (2024)

Cristiane Lauretti

Early Use of SGLT2 Inhibitors in Heart Failure With Preserved Ejection Fraction: Quantitative Analysis of Cardiac Biomarkers, Renal Function, and In-Hospital Mortality

Revista de Gestão Social e Ambiental 19(2) (2025)

Luiz Francisco de Souza Neto; Camila Maria Bertão Carvalho; Laura Emilly de Moura Bezerra; Luciano Victor Vasconcelos Saldanha; Artur Freire Brito; Kerolaine Silva Fonseca; Fernando Paniago Santini; Dionéa Ferreira Ayres Viana; Hildo Santiago Reis de Aguiar; Amanda Pinheiro Oliveira; Mariana Mota Benevides de Oliveira; Nelso Gabriel Lippo Turmina; Luis Guilherme Rodrigues de Almeida Moutinho; Rebeca Carvalho Wanderley de Lima Lôbo; Layanna Pessoa Marçal de Oliveira; Raul Santos; Aurélia Lorena Toscano de Medeiros Borges de Méllo; Levy Alves Pinto Loureiro; Dulce Cerqueira Ferreira Cavalcanti; Ana Clara Onofre Brito Chaves; José Mateus da Silva Bomfim; Ellen Pereira Areal; Maria Eduarda Morales Rodrigues; Rodrigo Porcionato; Joseane Oliveira Braga Nascimento; Harley Davidson Rocha de Lima; Giovana Mendelski Pereira

Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database

Frontiers in Medicine 13 (2026)

Minghui Yin; Hu Tan; Shan Xie; Yun Kuang; Qian Wu; Junlong Ma; Chengxian Guo

Место ингибиторов натрий - глюкозного котранспортера 2-готипа (SGLT2) в современной медикаментозной терапии сахарного диабета

Медицина: теория и практика 11(1) (2026)

Анна Борисовна Шаповалова; Виктор Владимирович Смирнов; М.М.А. Нгуба; Х.А.М. Ал

Key safety outcomes of SGLT2 inhibitors versus DPP ‐4 inhibitors in general and vulnerable participants with T2DM : A target trial emulation study

Diabetic Medicine (2026)

Chieh‐Li Yen; Pei‐Ru Li; Chao‐Yi Wu; Chung‐Ying Tsai; Jia‐Jin Chen; Chang‐Chyi Jenq; Hsiang‐Hao Hsu; Chang‐Fu Kuo; Lai‐Chu See; Huang‐Yu Yang